Barinthus Biotherapeutics Plc (BRNS) Stock Price, Financials & Summary

Price chart

Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14

Key dataSep 14, 2026

Open$0.74

From 52W high−53.16%

Volume0.00

Market cap$30.23M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 14, 2026

Open

$0.74

From 52W high

−53.16%

Volume

0.00

Market cap

$30.23M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.5x

P/E (TTM)

—

RSI (14)

60.2

MomentumView details →

1D Return

−2.49%

YTD Return

+5.70%

SummaryUpdated Jun 1, 2026

Barinthus Biotherapeutics plc (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Harwell, United Kingdom. Originally known as Vaccitech plc, the company rebranded to Barinthus Biotherapeutics in November 2023. The company went public in April 2021 and focuses on developing novel T cell immunotherapeutics designed to guide the immune system in treating chronic infectious diseases, autoimmune conditions, and cancer.

Ask drillr about Barinthus Biotherapeutics Plc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−73.14%

ROA (TTM)

−50.97%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+40.46%

FCF YoY

+31.46%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

−5.81%

EBITDA YoY

+40.02%

MomentumView details →

1D Return

−2.49%

YTD Return

+5.70%

1Y Return

−29.52%

RSI (14)

60.2

vs 50D SMA

+16.17%

vs 200D SMA

+12.33%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

5.54x

Quick Ratio

5.54x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.26

EPS Surprise

7.14%

Beats (12Q)

6/12

Next Q EPS Est

−$0.26

Avg Surprise (4Q)

27.50%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−41.74M

Op. CF (TTM)

−26.43M

Next earningsNov 6, 2026 →

Latest newsMore news →

Barinthus Biotherapeutics plc transferred its listing from NASDAQ to another exchange, as disclosed in an 8-K filing on August 24, 2026.27d ago

Barinthus Biotherapeutics plc completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease.45d ago

Similar companies

BeyondSpring Inc.BYSI Quince Therapeutics, Inc.QNCX Sangamo Therapeutics, Inc.SGMO ABVC BioPharma, Inc.ABVC Evaxion Biotech A/SEVAX TransCode Therapeutics, Inc.RNAZ Find similar companies →

Latest newsMore news →

Barinthus Biotherapeutics plc transferred its listing from NASDAQ to another exchange, as disclosed in an 8-K filing on August 24, 2026.27d ago Barinthus Biotherapeutics plc completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease.45d ago